http://orcid.org/0000-0002-0090-6289
References
- Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23:114-18
- American Academy of Dermatology. Psoriasis. 2017, Washington DC. Available at: https://www.aad.org/media/stats/conditions/psoriasis
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
- Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol 2015;151:651-8
- de Carvalho AV, Duquia RP, Horta BL, et al. Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs RD 2017;17:29-51
- Wu JJ, Rastogi S, Menges B, et al. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment. Presented at the American Academy of Dermatology Annual Meeting, San Diego, CA, February 16–20, 2018
- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014;70:512-16
- Ortho Dermatologics. Data on File. Bridgewater, NJ: Ortho Dermatologics; 2017
- Truven Health Analytics. Red Book. Ann Arbor, MI: Truven Health Analytics. 2017. Available at: http://www.micromedexsolutions.com/micromedex2/4.34.0/WebHelp/RED_BOOK/Introduction_to_REDB_BOOK_Online.htm
- Gu T, Shah N, Deshpande G, et al. Comparing biologic cost per treated patient across indications among adult US managed care patients: a retrospective cohort study. Drugs Real World Outcomes 2016;3:369-81
- Lin HC, Lucas PT, Feldman SR, et al. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatolog Treat 2012;23:196-202
- Baker EL, Coleman CI, Reinhart KM, et al. Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: systematic review and meta-analyses. Dermatol Ther (Heidelb) 2012;2:9
- Ahn CS, Gustafson CJ, Sandoval LF, et al. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol 2013;14:315-26
- Korman NJ, Zhao Y, Pike J, et al. Patient satisfaction with current psoriasis treatment: a real-world study in the USA. Dermatol Online J 2016;17;22
- Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol 2016;17:87-97
- Stearns RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9
- Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol 2015;73:585-593.e3
- Armstrong AW, Robertson AD, Wu J, et al. Patient satisfaction with current psoriasis treatment: a real-world study in the USA. JAMA Dermatol 2013;149:1180-5
- Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016;175:273-86
- Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015;373:1318-28
- Asche CV, Kim M, Feldman SR, et al. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. J Med Econ 2017;20:1000-6